Navigation Links
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Date:4/6/2011

acteria, including MRSA.

"Cubist has a proven track record and well established relations with all stakeholders involved in the antibiotics space.  We believe this collaboration will maximize the impact of and de-risk DIFICID's U.S. commercial launch, assuming approval," said Pedro Lichtinger, President and CEO of Optimer.  "Optimer plans to hire 100 sales representatives to target the 1,100 hospitals, which comprise about 70% of U.S. hospital CDI cases.  We also believe this collaboration with Cubist will allow us to accelerate formulary adoption, expand our market reach and penetration to up to 2,000 hospitals, comprising over 90% of U.S. hospital CDI cases, and commit resources to long-term care facilities that comprise approximately one-third of all CDI cases.  In addition, this provides the opportunity to capture the undiagnosed CDI market segment which some estimate to be as many as three million cases per year."

Cubist's President and CEO Michael Bonney said, "We believe that the strengths of Cubist's seasoned sales force, medical affairs team and our experience in the hospital will add tremendous value to Optimer's launch strategy and execution. We look forward to working with Optimer to introduce a much needed therapy for seriously ill patients suffering from CDAD."

The agreement expires two years from the first commercial sale of DIFICID.  The agreement can be renewed for additional terms upon agreement of the parties and can be terminated early by either party in certain defined situations. Optimer will be responsible for the manufacturing and distribution of DIFICID in the United States and for recording product revenue.  Optimer will be responsible for obtaining FDA approval, and will retain ownership of the New Drug Application.  For its efforts under the co-promotion agreement, including providing specified levels of resources and activities, Cubist will receive quarterly service fees of $3.75 mi
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
2. Trading Halted Today in Optimer Pharmaceuticals Stock
3. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
4. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
5. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
6. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
7. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
9. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
(Date:12/26/2014)... (PRWEB) December 26, 2014 It is said ... great dress. Today, UWDress.com, the famous wedding dress supplier, ... launches a site-wide cocktail gown promotion. , UWDress.com’s navy ... collection, and they come in high fashion styles. Simple dresses ... depending on the occasion; they are specially designed for those ...
(Date:12/26/2014)... December 26, 2014 “Many people become ... personal injury claim issues and phone calls with insurance ... an article featuring their free eBook on pedestrian ... eBook on pedestrian and bicycle auto accident claims assures ... fully capable of professionally handling their case while they ...
(Date:12/25/2014)... The microscopy market is estimated to grow ... million by 2019. Optical microscopy is the largest ... product segment is expected to show the fastest ... on nanotechnology, technological advancements, and increasing federal support ... Get Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... million Americans, OptumHealth developed myOptumHealth.com to provide individuals seeking health ... easy-to-understand and actionable content, tools and resources. , ... ... -- OptumHealth Inc., the health and wellness business of UnitedHealth ...
... Medical Record and practice billing solutions for the healthcare industry, is ... Chief Commercial Officer. Flormann brings 25 years of experience in ... market development to Glenwood Systems. , ... Waterbury, CT ...
... University of Utah researchers have developed an automobile ignition ... sending text messages while driving. , The university has obtained ... a private company that hopes to see it on the ... $50 per key plus a yet-undetermined monthly service fee. ...
... Calif., Dec. 10 PADRES Contra El Cancer, an,organization ... children,with cancer and their families, will host its Annual ... 13, 2008. , ... afternoon playing,and sledding amongst 40 tons of snow while ...
... Walter Reed Soldiers Visit Atlantic City , , ... of a soldier who had been wounded in the Iraq conflict and ... the invitation for a visit to Harrah,s Resorts in Atlantic City. , ... young servicemen and women, recovering , from war injuries and ...
... (NYSE: VAR ) announced today that it will report ... of regular trading on Thursday, January 29, 2009. The news ... parties at 2:00 p.m. PT. , , ... January 29, 2009. The news release and information on the conference ...
Cached Medicine News:Health News:OptumHealth Launched myOptumHealth.com, Health and Wellness Information Destination with Clinically Reviewed Content, Tools and Resources 2Health News:OptumHealth Launched myOptumHealth.com, Health and Wellness Information Destination with Clinically Reviewed Content, Tools and Resources 3Health News:OptumHealth Launched myOptumHealth.com, Health and Wellness Information Destination with Clinically Reviewed Content, Tools and Resources 4Health News:OptumHealth Launched myOptumHealth.com, Health and Wellness Information Destination with Clinically Reviewed Content, Tools and Resources 5Health News:Glenwood Systems, LLC Appoints Ron Flormann Chief Commercial Officer 2Health News:Car key jams teen drivers' cell phones 2Health News:Car key jams teen drivers' cell phones 3Health News:Car key jams teen drivers' cell phones 4Health News:PADRES Contra El Cancer to Host its 10th Annual Posada Holiday Celebration for Children with Cancer 2Health News:Wounded Warriors to be Holiday Guests of Harrah's Entertainment 2Health News:Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call 2Health News:Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: